Sykehuset Oestfold HF Kalnes — Clinical Trial Site

27 Registered trials

13 Currently recruiting

Organisation

Sykehuset Oestfold HF Kalnes

Location

Graalum, Norway

Identifier

ORG-100041783

Address

Kalnesveien 300, 1714, Norway

Departments

-
#3150 - Kreft og hematologisk avdeling, trombose poliklinikk
Department of Cardiology
Department of Medicine
Department of Nephrology
Department of Obstetrics and Gynecology
Department of Oncology
Gastroenterologisk avdeling
Hematology
Hjertemedisinsk avdeling
Infectious Diseases
Kardiologisk avdeling
Neurology
Nevrologisk avdeling
Oncology
Ophthalmology
Outpatient clinic for cancer and blood diseases
Øre-nese-hals avdeling
Pediatrics
Senter for lindrende behandling

Clinical trials at this site (27)

Search interface

Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-… Recruiting

2024-511346-39-00 Immune-mediated necrotizing myopathy 3 2025-03-28
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4) Recruiting

2023-507067-19-00 Autoimmune Cytopenias (warm autoimmune hemolytic anemia 4 2024-05-15
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 … Recruiting

2024-517606-29-00 Central retinal artery occlusion 5 2020-10-30
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af… Recruiting

2025-522400-24-00 Metastatic urothelial cancer 10 2026-01-27
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial … Recruiting

2023-509022-22-00 Pancreatic ductal cancer 5 2025-08-21
The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind tr… Recruiting

2024-517981-40-00 Chronic Migraine 5 2025-06-06
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
The CORTAD study Recruiting

2024-512888-31-00 Primary adrenal insufficiency (PAI) 11 2023-08-03
Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness Recruiting

2024-510798-84-00 Idiopathic sudden sensorineural hearing loss (ISSNHL) 10 2022-01-28
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
The Norwegian Antibiotics for Pneumonia in Children (NAPIC) Study Recruiting

2024-512001-39-01 Lower respiratory tract infection 6 2018-02-01
RElapse from Mrd Negativity As iNdication for Treatment Ended

2023-510215-18-00 Multiple myeloma 10 2024-09-26
A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen… Ended

2024-512890-28-00 Primary immune thrombocytopenia (ITP) 5 2023-03-20
A double-blind randomized placebo-controlled four-arm trial to assess the efficacy of oral bicarbonate and intravenous butylscopolamine brom… Ended

2024-511848-55-00 childbirth 5 2023-01-03
An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended

2022-502122-41-00 Clear cell renal cancer 5 2021-05-11
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch… Ended

2022-502354-14-00 Completely resected Stage IIb/c melanoma 5 2019-10-28
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi… Ended

2022-500594-13-00 "Non-Alcoholic Steatohepatatis (NASH) is the progressiv 4 2022-12-14
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 SARS CoV-2 (COVID-19) 4 2022-08-24
Cohort study of human mpox virus disease Ended

2022-501132-42-00 Monkeypox virus disease 6 2022-08-02